Tuesday, 1 October 2019

Fungal Endocarditis Market 2019 Share, Trend, Segmentation and Forecast to 2023

Market Scenario
Fungal endocarditis is an infection of the heart’s inner lining, known as the endocardium. The etiologic fungi more commonly observed are the Candida and Aspergillus species.
The gold standard for the diagnosis of fungal endocarditis is culture and the isolation of etiologic agents from infected valves, emboli, and other materials collected by different invasive methods such as surgery.
A number of factor such as rising incidents of fungal endocarditis, increasing awareness about fungal infections, improving regulatory framework, increasing government assistance, and rising funding and reimbursement are propelling the growth of the global fungal endocarditis market.
However, challenges in research and development, side-effects of treatment, presence of misbranded and spurious drugs and poor healthcare system in low and middle-income countries may hamper the growth of the market.
It is estimated that the fungal endocarditis market is expected to grow at a CAGR 4.2% during the forecast period of 2017-2023.
Key Players
Some of key the players in the global fungal endocarditis market are Pfizer, Merck & Co., Sanofi, Astellas Pharma, Inc., GlaxoSmithKline plc, Novartis AG, Enzon Pharmaceuticals, Inc., Bayer AG, Sigma-Aldrich, Abbott Laboratories, Eli Lily and Company, and Others. 
Segmentation
The global fungal endocarditis market is segmented on the basis of type of causative agent, diagnosis, treatment, and end-user.
On the basis of the treatment, the market is classified as antifungal medication, surgery, and combined treatment. The antifungal medication is further segmented into voriconazole, amphotericin B (AMB), itraconazole, caspofungin, echinocandins, and others.
On the basis of the type of causative agent, the market is segmented into Candida species
Aspergillus species, and Histoplasma capsulatum.
On the basis of the diagnosis, the market is classified into physical examination, blood test, X-ray, echocardiography, and electrocardiogram
On the basis of the end-users, the market is segmented into hospital, clinics, diagnostic centers, and others.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Friday, 27 September 2019

Coronary Stents Market to Observe Significant Growth by 2019

Market Scenario:
Market Research Future adds the “Coronary Stents Market Research Report - Global Forecast till 2023” report to their unique collection and states that, Global Coronary Stents Market is expected to grow significantly over the forecast period. The market held a market value of USD 9,382.63 Million in 2017 and is projected to grow at a CAGR of 7.81% over the forecast period.
Coronary stents are used in the process of angioplasty to make the cross-section of the blood vessel wider. Stents hold the walls of the vessel and thus do not let it sag or shrink, thereby curing the blockages in the vessel. Coronary stents have substantially changed the practice of interventional cardiology by reducing early complications such as abrupt vessel closure and improving late clinical outcome (restenosis). This results in patient and physician satisfaction. Thus, this factor contributes heavily to the growth of this market.
Moreover, the wide acceptance of prosthesis in coronary artery treatment procedures also fuels the market growth. Key companies are also engaged in new product launches related to coronary stents owing to the wide acceptance of the product. For instance, in May 2018, Terumo Europe NV announced the launch of Ultimaster Tansei drug eluting stent in Europe.
The market, by coronary stents, is further segmented into drug eluting stents, bare metal stents, and bioresorbable vascular scaffolds. Drug-eluting stents are metal stents that have been coated with a pharmacologic drug known to suppress restenosis, whereas bare metal stents are stents without a covering or a coating. Bioresorbable vascular scaffolds are intended to provide mechanical support and drug delivery similar to drug eluting stents, followed by complete resorption in some years.
Key players:
Abbott, B. Braun Melsungen AG, Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical, Elixir Medical Corporation, Medtronic plc, Meril Life Sciences, MicroPort Scientific Corporation, Stentys SA, and Terumo Corporation are some of the key players in the global coronary stents market.
Segmentation:
Global Coronary Stents Market has been segmented into products, and end user.Based on products, the market has been segmented into, Drug Eluting Stents, Bare Metal Stents, and Bioresorbable Vascular Scaffolds. The drug eluting stent segment is expected to account for the largest share in the global coronary stents market in 2017. This large share is majorly attributed to the wider acceptance of the drug eluting stents in the angioplasty procedures, better patient compliance as compared to the bare metal stents. On the other hand, bioresorbable stents are projected to grow at the fastest rate during the forecast period. 
European Coronary Stents Market has been segmented into Western Europe and Eastern Europe where-in Western Europe region is further divided into Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Coronary Stents Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The coronary stents market in the Middle East & Africa has been segmented into the Middle East and Africa.
On the basis of end users, the market has been segmented into hospitals & clinics, ambulatory surgical centres, specialty centres, and others. The hospitals & clinics segment is expected to account for the largest share in the global coronary stents market in 2017. At the same time, the increasing establishments of the ambulatory surgical centres in the developed and developing countries has led this segment to grow at the fastest rate during the forecast period.Based on the regions, the market for coronary stents is segmented in to, the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The coronary stents market in the Americas region has further been segmented into North America and South America, where-in the North American market is further divided into the US and Canada.
Browse Complete 130 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/coronary-stents-market-6938

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Top trends in Gestational Trophoblastic Disease Market by 2019

Market Scenario:
Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.
The global gestational trophoblastic disease market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.
Competitive Landscape:
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Antares Pharma
  • Mylan N.V.
  • Novartis AG
  • BP Pharmaceuticals Laboratories Company
  • Fresenius Kabi AGAccord Healthcare, Inc.
  • Eli Lilly and Company
  • Sanofi
  • Bayer AG
  • Amgen Inc.
  • Merck
Segmentation:The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.
The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.
The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease,  whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.
The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.
The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.
The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.
The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/gestational-trophoblastic-disease-market-6558
Regional Market Summary
Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.
Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Wednesday, 25 September 2019

Pathological Microscopes Market 2019 Market Challenge, Driver, Trends & Forecast to 2023

Market Scenario
The global pathological microscopes market size is estimated to accrue USD 523.20 million by 2023, states Market Research Future (MRFR) in its latest report.  Increasing prevalence of various diseases is the primary driver of the market. High incidence of cancer, tuberculosis, and diabetes among adults and children has called for advanced diagnostic procedures which can detect the symptoms at an early stage. This is expected to bolster the demand of the pathological microscopes market among its end-users. The market can exhibit 4.50% CAGR over the forecast period (2019-2023).
Pathological microscopes are devices used in detection of pathogens and rapid diagnosis of diseases. Blood tests and tissue samples are taken by pathologists to discern and identify their presence. Parameters considered include white blood cell (WBC) count, red blood cell (RBC) count, and platelets, and others.
Pathology concerns itself with the study of diseases via cell, tissue, and blood samples. The evolution of virus and disease strains calls for the need of advanced technological solutions. Pathological microscopes are used to identify or discern the presence of chronic or infectious diseases in the body by pathologists. The global pathological microscopes market is set to touch a valuation of USD 523.20 million by 2023. It can accrue significant revenue at 4.50% CAGR over the forecast period (2018-2023).
Increasing prevalence of chronic diseases, emergence of public and private diagnostic centers, and automation in laboratories are factors driving market growth. But unfavorable reimbursement schemes and high costs of microscopes can pose a challenge to the market.
Competitive Analysis
Microscope manufacturers in the pathological microscopes market include Nikon Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Olympus Corporation (Japan), ZEISS International (Germany), Labomed, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Euromex Microscopen BV (The Netherlands), Bruker Corporation (U.S.), Sakura Finetek USA, Inc. (U.S.), and Celestron LLC (U.S.).
The players are focusing on integrating new technologies to expedite the diagnosis rate associated with microscopes and lower the mortality rate. Collaborations, new product launches, and partnerships are strategies being adopted to gain a larger market share.
Segmentation
The pathological microscopes market is segmented by type, application, and end-user.
By type, electron microscope held close to 41.4% share in 2017, followed by optical microscope (18.8%), compound microscope (13.5%), digital microscope (5.4%), fluorescence microscope (4.4%), and others (16.5%). Electron microscopes can generate nearly USD 217.81 million by 2023 owing to their application in life sciences. Prevalence of diseases such as anemia and leukemia which require the need of electron microscopes lend credence to the segment valuation. But digital microscopes can exhibit the highest CAGR of 5.01% during the forecast period to accumulate USD 28.90 million for the pathological microscopes market by 2023.
By end-user, pathology & diagnostic laboratories accounted for 45.2% market share in 2017, followed by hospitals & clinics (38.6%), forensic laboratories (11.5%), and others (4.7%). Hospitals & clinics will be the biggest end-user of the pathological microscopes market by 2023. It can generate USD 206.25 million by the end of the forecast period owing to the setup of various branches of hospital chains to handle high patient volume. On the other hand, pathology & diagnostic laboratories can generate USD 239.73 million by 2023 thanks to possessing various skilled personnel and use of hematology, clinical microbiology, and molecular pathology for rapid diagnosis of diseases.
By application, bodily fluids accounted for 79.4% share of the pathological microscopes market in 2017, followed by tissue scanning (12.7%), and others (7.9%). Bodily fluids can generate USD 418.84 million for the pathological microscopes market by 2023. This can be attributed to use of fluid samples to identify the presence of diseases such as tuberculosis in the human body. High prevalence of blood disorders is driving the segment growth. On the other hand, tissue scanning is touted to accumulate USD 67.94 million by 2023. High prevalence of cancer and use of digital microscopes to detect abnormal tissue growth can fuel the segment growth.
Regional Analysis
Region-wise, the pathological microscopes market covers trends and opportunities across Asia Pacific (APAC), Americas, Europe, and the Middle East & Africa (MEA). The Americas region is expected to dominate the market owing to mushrooming of various research and academic institutes. Investments in research and development (R&D) coupled with development of healthcare infrastructure are factors expected to spur the regional market growth. On the other hand, the APAC region is projected to induce massive demand owing to rising funding in nanotechnology, low material costs, and availability of skilled professionals.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Atherectomy Devices Market 2019 - Opportunity, Driving Trends and deep study 2023

Market Scenario
Atherectomy devices are built to either shave, cut, vaporize, laser or sand the plaques. The devices come with different indications. Different atherectomy devices have been invented for commercial use. The location of the plaque and type of blockage influence the choice of atherectomy device to be used. Some atherectomy devices are used only in the larger arteries on the upper portion of the knee, while other devices come with smaller catheters that are suitable for operating the arteries below the knee.
Atherectomy is a technique applied to eliminate atherosclerotic plaque from affected arteries. The plaques are in either peripheral or coronary arterial vasculature and may have distinct characteristics depending on the nature of the plaque. Atherectomy is used widely in cure of both peripheral and coronary arterial ailments. It is a minimally invasive endovascular surgery.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7322
The worldwide Atherectomy devices market is likely to develop remarkably over the forecast period. It is projected that the global atherectomy devices market will register a CAGR of 6.12% over the forecast period of 2018–2023. In 2017, the estimated market value was around 1.09 billion.
The growing rate of peripheral and coronary arterial diseases coupled with increasing demand for minimally invasive techniques is predicted to boost the growth of the atherectomy devices market. Minimally invasive surgical techniques deliver quicker recovery, quick procedural time, lesser risk of infections and complications. The worldwide atherectomy devices market is likely to witness noteable surge in demand due to exponential growth in the incidence of lifestyle-related ailments and elderly population.
Segmentation
The global atherectomy devices market is segmented on the basis of product type, application, and end user.
Based on application, the atherectomy devices market is segmented into cardiovascular, neurovascular, peripheral vascular, and others.
The atherectomy devices market, by product type is categorised into directional atherectomy systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.
The directional atherectomy systems segment is expected to hold the largest share owing to the high treatment rate, whereas the photo-ablative (laser) atherectomy systems is expected to be the fastest growing segment owing to the growing preference by surgeons.
On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, and others.
On the basis of region, the global atherectomy devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The atherectomy devices market in the Middle East and Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Asia-Pacific was projected to be the fastest growing region for the global atherectomy devices market. This owes to the technological advancements resulting in the development of cost-effective atherectomy devices leading to high acceptance rate for the devices in the Asia-Pacific region. The Middle East and Africa holds the least share in the global atherectomy devices market due to the presence of economically diverse countries, and less initiatives taken by the government.
It is projected that the Americas dominated the global atherectomy devices market owing to the growth of the market in the North American region. This is largely attributed to the factors such as increase in research funding, and growing awareness about the high-end atherectomy devices among medical professionals. Europe is expected to hold the second largest share in the atherectomy devices market owing to growing healthcare infrastructure. Additionally, various initiatives by public and private organizations is anticipated to boost the growth of the atherectomy devices market.
Browse Complete 160 Pages Premium Research Report @ https://www.marketresearchfuture.com/reports/atherectomy-devices-market-7322
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Handheld Surgical Devices Market Definition, Symptoms and Treatments Review 2019

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Anti-Hypertensive Drugs Market over the forecast period. 
According to a recent study report published by the Market Research Future, The global market of  Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the market is anticipated to observe a sluggish growth; at a CAGR of 2.73% during 2016 to 2022.
Competitive Analysis
Key players in the antihypertensive drugs market are Sanofi S.A. (France), Novartis AG (Switzerland), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Takeda Pharmaceutical Company (Japan), Merck KGaA (Germany), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), and United Therapeutics Corporation (U.S.). The market is characterized by expiry of various patented drugs and entry of generics. Players are taking measures to regain their lost standing by investing in research and development and launch of new products.
Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.
The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.
Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.
Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.
Segmentation
The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;
Segmentation By Pharmacological Class               : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other.
Segmentation By Hypertension Type                      : Comprises Systemic and Pulmonary Hypertension Drugs and other.
Segmentation By Disease Source                              : Comprises Primary and Secondary.
Segmentation By Regions                                            : Comprises Geographical regions - North America, Europe, APAC and Rest of the World.
Regional Analysis
The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.
The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.
The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @  https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Tuesday, 24 September 2019

Handheld Surgical Devices Market size and Key Trends in terms of volume and value 2019

Market Scenario:
The Global handheld surgical devices market is expected to grow at an approximate CAGR of 6.8% during forecast period, 2019–2023.
The hand held surgical devices are specially designed for specific surgeries. These are available in a wide variety of shapes and sizes.
Increasing number of surgical procedures is the key factor driving the handheld surgical devices market. According to the Australian Institute of Health and Welfare, during 2015–16, there were 10.6 million hospitalisations, and 1 in 4 hospitalisations involved a surgical procedure.
Various other factors such as increasing incidence of accidents, high geriatric population, technological advancements, increasing demand for plastic & reconstructive surgery, and rising patient awareness regarding the benefits of handheld surgical devices are also expected to propel the growth of the market.
Key players
Some of the key players in the global handheld surgical devices market are B. Braun Melsungen AG, Integra LifeSciences Corporation, Zimmer Biomet Holdings, Pelion Surgical, Medtronic, Smith & Nephew, Johnson & Johnson, Millennium Surgical Corp, Medicon Eg, Elite Medical, Becton, Dickinson and Company (BD), Thompson Surgical, Stryker, Aspen Surgical, KLS Martin, CooperSurgical Inc., and others.
Segmentation
The global handheld surgical devices market is segmented based on application, product, end user and region.
The global market for handheld surgical devices, by application is segmented into neurology, urology, orthopedics, gynecology, cardiovascular, wound closure, and others.
The market, by product, is segmented into forceps and spatulas, retractors, dilators, graspers, auxiliary devices, cutter devices, and others. The auxiliary devices segment is further classified as clamps, cannulas, and closure devices. The cutter devices segment is further classified as trocars, lancets, and scissor. The others segment includes punches, curettes, blunt dissectors, and snares.
Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centres, research and academic institutes, and others. Clinics held a lucrative market share in 2017 due to rising prevalence of chronic conditions.
Regional Analysis
The Americas dominated the global market for handheld surgical devices owing to the increasing prevalence of chronic conditions, and high geriatric population.
In 2017, it was estimated that Europe stood second in the global handheld surgical devices market. This can be attributed to the increasing cases of surgical procedures, and rising research and development investments. According to the 2016 data suggested by Eurostat, around 1040.8 cases of cataract surgery and 406.2 cases of transluminal coronary angioplasty are registered in Germany.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing healthcare sector, increasing penetration of the market players within the region, increasing healthcare expenditure, a rising number of surgical procedures drive the regional markets of the Asia Pacific region. On the other hand, the Middle East and Africa held least share in the global handheld surgical devices market due to the low per capita income, especially within the African region.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/handheld-surgical-devices-market-7210
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)